CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT
Zaigham Saghir(Gentofte Hospital), Jesper Holst Pedersen(Reykjavík Energy (Iceland)), Martin Døssing(Frederiksberg Hospital), Haseem Ashraf(University of Oslo), Klaus Richter Larsen(Bispebjerg Hospital), John Brodersen(University of Copenhagen), Niels Seersholm, Asger Dirksen, Jakob Fraes Rasmussen(University of Copenhagen), Jann Mortensen(Copenhagen University Hospital), Klaus F. Kofoed(University of Copenhagen), Philip Tønnesen(Gentofte Hospital), Paul Frost Clementsen(Gentofte Hospital), Birgit Guldhammer Skov(Gentofte Hospital), Hanne Helene Hansen(University of Copenhagen), Karen Skjøldstrup Bach(Gentofte Hospital), Hanne Thorsen(University of Copenhagen)
Cited by 391
Related Papers
Detection and characterization of lung cancer using cell-free DNA fragmentomes
|Nature Communications|2021|458
The Danish Randomized Lung Cancer CT Screening Trial—Overall Design and Results of the Prevalence Round
|Journal of Thoracic Oncology|2009|440
Overdiagnosis: what it is and what it isn’t
|BMJ Evidence-Based Medicine|2018|368
Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling
|American Journal of Respiratory and Critical Care Medicine|2015|343
Long-Term Psychosocial Consequences of False-Positive Screening Mammography
|The Annals of Family Medicine|2013|342